Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.38 |
| ▸ | MEN1 | O00255 | 2/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.38 |
| ▸ | NUDT1 | P36639 | 2/20 | 0.38 |
| ▸ | MASP2 | O00187 | 1/20 | 0.38 |
| ▸ | AOC3 | Q16853 | 1/20 | 0.38 |
| ▸ | HPGD | P15428 | 2/20 | 0.36 |
| ▸ | USP2 | O75604 | 1/20 | 0.36 |
| ▸ | TP53 | P04637 | 1/20 | 0.36 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.36 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.36 |
| ▸ | MAPK3 | P27361 | 1/20 | 0.36 |
| ▸ | XDH | P47989 | 1/20 | 0.36 |
| ▸ | HBB | P68871 | 1/20 | 0.36 |
| ▸ | PAX8 | Q06710 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | FABP6 | P51161 | 1/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.35 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29802574 | 1.00 | ALDH1A1 (0.38) | ALDH1A1MEN1KMT2ANUDT1MASP2 | |
| Pyridine SCHEMBL422990 | 0.88 | ADORA2A (0.36) | ALDH1A1MEN1KMT2ANUDT1MASP2 | |
| SCHEMBL5942175 | 0.79 | BCL6 (0.35) | ALDH1A1BCL6 | |
| SCHEMBL2934831 | 0.79 | ADORA2A (0.35) | ALDH1A1CLK1 | |
| SCHEMBL23963663 | 0.79 | FABP6 (0.41) | ALDH1A1MEN1KMT2ANUDT1MASP2 | |
| SCHEMBL28281755 | 0.76 | ALDH1A1 (0.44) | ALDH1A1MEN1KMT2ANUDT1MASP2 | |
| SCHEMBL25451172 | 0.75 | FABP6 (0.34) | ALDH1A1MEN1KMT2ANUDT1MASP2 | |
| SCHEMBL25449335 | 0.75 | L3MBTL1 (0.42) | ALDH1A1NUDT1SMN1; SMN2 | |
| SCHEMBL29941324 | 0.75 | FABP6 (0.34) | ALDH1A1MEN1KMT2ANUDT1MASP2 | |
| SCHEMBL25377896 | 0.75 | KDM4E (0.38) | ALDH1A1HPGDKDM4EHSD17B10LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3464287-B1 | ANIMAL AND HUMAN ANTI-MALARIAL AGENTS | CELGENE CORP (US) | 2022-06-08 | — | — | EP | claimed |
| WO-2020159447-A1 | METHOD OF SYNTHESIZING SINGLE-STRANDED NUCLEOTIDE SEQUENCE, BLOCKED NUCLEOSIDE TRIPHOSPHATES AND RELATED METHODS | AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (SG) | 2020-08-06 | — | — | WO | claimed |
| EP-3464312-A1 | ANIMAL AND HUMAN ANTI-TRYPANOSOMONAL AND ANTI-LEISHMANIA AGENTS | Celgene Corporation (US) | 2019-04-10 | — | — | EP | claimed |
| WO-2017210408-A1 | ANIMAL AND HUMAN ANTI-TRYPANOSOMONAL AND ANTI-LEISHMANIA AGENTS | CELGENE CORPORATION (US) | 2017-12-07 | — | — | WO | claimed |
| WO-2023104155-A1 | LIGAND COMPOUNDS FOR E3 UBIQUITIN LIGASE, PROTEIN DEGRADERS DEVELOPED ON BASIS OF LIGAND COMPOUNDS, AND USES THEREOF | 标新生物医药科技(上海)有限公司 | 2023-06-15 | — | — | WO | disclosed |
| EP-3724355-A1 | POLYA TAIL LENGTH ANALYSIS OF RNA BY MASS SPECTROMETRY | Novartis AG (CH) | 2020-10-21 | — | — | EP | disclosed |
| WO-2020159447-A1 | METHOD OF SYNTHESIZING SINGLE-STRANDED NUCLEOTIDE SEQUENCE, BLOCKED NUCLEOSIDE TRIPHOSPHATES AND RELATED METHODS | AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (SG) | 2020-08-06 | — | — | WO | disclosed |
| US-10420771-B2 | Animal and human anti-malarial agents | CELGENE CORPORATION (US) | 2019-09-24 | — | — | US | disclosed |
| WO-2019116346-A1 | POLYA TAIL LENGTH ANALYSIS OF RNA BY MASS SPECTROMETRY | NOVARTIS AG (CH) | 2019-06-20 | — | — | WO | disclosed |
| US-20180280398-A1 | ANIMAL AND HUMAN ANTI-MALARIAL AGENTS | CELGENE CORP (US) | 2018-10-04 | — | — | US | disclosed |
| EP-3142483-A1 | HUMANIZED C5 AND C3 ANIMALS | Regeneron Pharmaceuticals, Inc. (US) | 2017-03-22 | — | — | EP | disclosed |
| WO-2015171523-A1 | HUMANIZED C5 AND C3 ANIMALS | REGENERON PHARMACEUTICALS, INC. (US) | 2015-11-12 | — | — | WO | disclosed |
| US-20110098267-A1 | TOPICAL FORMULATIONS FOR THE TREATMENT OF PSORIASIS | SYNTA PHARMACEUTICALS CORPORATION (US) | 2011-04-28 | — | — | US | disclosed |
| US-4644069-A | HEATING MALEIC ACID OR ANHYDRIDE WITH AN AMIDINE OR ITS SALT | CIBA-GEIGY CORPORATION (US) | 1987-02-17 | — | — | US | disclosed |
| US-4639531-A | HETEROCYCLIC AMIDINE CATALYST | CIBA-GEIGY CORPORATION (US) | 1987-01-27 | — | — | US | disclosed |
| US-4511492-A | Electrically conducting aromatic azopolymers and method of preparation | UOP INC. (US) | 1985-04-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110098267-A1 | TOPICAL FORMULATIONS FOR THE TREATMENT OF PSORIASIS | IL17A, IL23R, IL15 | ALDH1A1 1903/4885MEN1 4796/4885KMT2A 4300/4885 |
| US-10420771-B2 | Animal and human anti-malarial agents | HPRT1, UMPS, PNP | ALDH1A1 1270/4885MEN1 2480/4885KMT2A 3900/4885 |
| US-20180280398-A1 | ANIMAL AND HUMAN ANTI-MALARIAL AGENTS | HPRT1, UMPS, PNP | ALDH1A1 1152/4885MEN1 2525/4885KMT2A 3936/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.